Shots: The P-IV IXORA-R study involves assessing of Taltz vs Tremfya (guselkumab) in 1,027 patients with moderate to severe plaque psoriasis for a total of 24 wks., with the primary […]readmore
Tags : P-IV
Shots: The P-IV VERIFY study involves assessing of Galvus (50mg, bid) + Metformin (1000–2000 mg, qd) vs SOC monothx. approach with metformin initiated in treatment naïve patients (n=2001) in a […]readmore
Shots: The P-IV IXORA-R study involves assessing of Taltz (160 mg at wk 0, followed by 80 mg at wks. 2, 4, 6, 8, 10, and 12, then 80 mg, […]readmore
Shots: The P-IV Early AMPLE mechanistic study results involve assessing of Orencia (125 mg, SC) vs adalimumab (40mg, SC) on a background of MTX in 80 patients in a ratio […]readmore
Shots: The P-IV PLUS study involves assessing of Mirabegron(25mg,50mg) vs PBO in 715 men patients with overactive bladder (OAB) symptoms receiving tamsulosin for lower urinary tract symptoms (LUTS) due to […]readmore